Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (1039)	10/16/2000 5:48:21 PM
From: Londo	Read Replies (1) \| Respond to of 1298

You'd think that, right? Personally, I do include the $240M cash in my projections, mainly because that cash will accrue 6% interest along the way (that's roughly 14-15 million dollars interest right there). Note that the sale of further ABGX stock will incur a rather large capital gains rate - when CEGE sold off a good deal of ABGX during the last secondary, I think they did just enough so they could write off their previous losses. But in regards to the actual price of stock, CEGE is trading in no-man's land.. almost nobody that chooses to invest in this company realizes that if the market hasn't recognized CEGE's assets in the past year, it probably won't in the next year, either. Best way to take advantage of it in the meantime? Sell some out-of-the-money calls.. when CEGE finally does break out, it should be so obvious that you'd be able to reverse the decision without too much cost. Selling calls is an easy way to raise cash in the meantime.